Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 141

1.

Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin.

Stephens JM, Gao X, Patel DA, Verheggen BG, Shelbaya A, Haider S.

Clinicoecon Outcomes Res. 2013 Sep 16;5:447-57. doi: 10.2147/CEOR.S46991. eCollection 2013.

PMID:
24068869
[PubMed]
Free PMC Article
2.

Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis.

Bounthavong M, Zargarzadeh A, Hsu DI, Vanness DJ.

Value Health. 2011 Jul-Aug;14(5):631-9. doi: 10.1016/j.jval.2010.12.006. Epub 2011 May 8.

PMID:
21839399
[PubMed - indexed for MEDLINE]
4.
5.

Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.

McKinnon PS, Sorensen SV, Liu LZ, Itani KM.

Ann Pharmacother. 2006 Jun;40(6):1017-23. Epub 2006 May 23.

PMID:
16720705
[PubMed - indexed for MEDLINE]
6.

Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.

De Cock E, Krueger WA, Sorensen S, Baker T, Hardewig J, Duttagupta S, Müller E, Piecyk A, Reisinger E, Resch A.

Infection. 2009 Apr;37(2):123-32. doi: 10.1007/s15010-008-8046-7. Epub 2009 Mar 9.

PMID:
19277465
[PubMed - indexed for MEDLINE]
7.

Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.

Patel DA, Shorr AF, Chastre J, Niederman M, Simor A, Stephens JM, Charbonneau C, Gao X, Nathwani D.

Crit Care. 2014 Jul 22;18(4):R157. [Epub ahead of print]

PMID:
25053453
[PubMed - as supplied by publisher]
8.

Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.

Campbell ML, Marchaim D, Pogue JM, Sunkara B, Bheemreddy S, Bathina P, Pulluru H, Chugh N, Wilson MN, Moshos J, Ku K, Hayakawa K, Martin ET, Lephart PR, Rybak MJ, Kaye KS.

Ann Pharmacother. 2012 Dec;46(12):1587-97. doi: 10.1345/aph.1R211. Epub 2012 Dec 4.

PMID:
23212935
[PubMed - indexed for MEDLINE]
9.

Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model.

Vinken A, Li Z, Balan D, Rittenhouse B, Wilike R, Nathwani D.

J Hosp Infect. 2001 Dec;49 Suppl A:S13-24.

PMID:
11926436
[PubMed - indexed for MEDLINE]
10.

Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model.

Bounthavong M, Hsu DI, Okamoto MP.

Int J Clin Pract. 2009 Mar;63(3):376-86. doi: 10.1111/j.1742-1241.2008.01958.x. Review.

PMID:
19222624
[PubMed - indexed for MEDLINE]
11.

Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.

Bounthavong M, Hsu DI.

Curr Med Res Opin. 2010 Feb;26(2):407-21. doi: 10.1185/03007990903454912.

PMID:
20001574
[PubMed - indexed for MEDLINE]
12.

Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.

Itani KM, Biswas P, Reisman A, Bhattacharyya H, Baruch AM.

Clin Ther. 2012 Aug;34(8):1667-73.e1. doi: 10.1016/j.clinthera.2012.06.018. Epub 2012 Jul 6.

PMID:
22770644
[PubMed - indexed for MEDLINE]
13.

Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model.

Shah NP, Reddy P, Paladino JA, McKinnon PS, Klepser ME, Pashos CL.

Curr Med Res Opin. 2004 Jun;20(6):779-90.

PMID:
15200734
[PubMed - indexed for MEDLINE]
14.

The impact of initial antibiotic therapy (linezolid, vancomycin, daptomycin) on hospital length of stay for complicated skin and soft tissue infections.

Szczypinska E, Velazquez A, Salazar D, Deryke CA, Raczynski B, Wallace MR.

Springerplus. 2013 Dec 30;2:696. doi: 10.1186/2193-1801-2-696. eCollection 2013.

PMID:
24422184
[PubMed]
Free PMC Article
16.

European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.

Bassetti M, Baguneid M, Bouza E, Dryden M, Nathwani D, Wilcox M.

Clin Microbiol Infect. 2014 Apr;20 Suppl 4:3-18. doi: 10.1111/1469-0691.12463.

PMID:
24580738
[PubMed - in process]
17.

Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections.

Patanwala AE, Erstad BL, Nix DE.

Curr Med Res Opin. 2007 Jan;23(1):185-93.

PMID:
17257479
[PubMed - indexed for MEDLINE]
18.
19.

Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species.

McCollum M, Rhew DC, Parodi S.

Clin Ther. 2003 Dec;25(12):3173-89.

PMID:
14749155
[PubMed - indexed for MEDLINE]
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk